Product Information
SEROQUEL XR 200 MG TABLET is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $15.5218 per EA under NDC 00310028260. Its NADAC has been published 399 times since Nov 28, 2013.
FDA first approved this application on May 17, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the quetiapine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
200 mg/1
Manufacturer
AstraZeneca Pharmaceuticals LPNDC
00310028260
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
11/20/2024
Active Ingredients
QUETIAPINE FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA022047FDA Approved
5/17/2007
TE Code
AB
On Market Since
7/16/2007
Pharmacological Classes
Price Statistics
The NADAC for SEROQUEL XR 200 MG TABLET has been published 399 times since Nov 28, 2013, and over the history we have for it it has risen 25.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.5218 per EA |
|---|---|
| All-time high | $15.7533 (Dec 12, 2018) |
| All-time low | $12.2854 (Dec 18, 2013) |
| 52-week high | $15.5218 |
| 52-week low | $15.5218 |
| Median price | $15.5531 |
| Average price | $15.1367 |
| Largest weekly change | +10.0% (Jan 8, 2014) |
| Weeks tracked | 399 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
0.0%
3Y
-0.2%
5Y
-0.2%
All
+25.2%
Last surveyed Nov 12, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of SEROQUEL XR 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SEROQUEL XR 200 MG TABLET, manufactured by AstraZeneca Pharmaceuticals LP, is $15.5218 per EA (NDC 00310028260), effective Nov 12, 2025.
How has the price of SEROQUEL XR 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for SEROQUEL XR 200 MG TABLET has risen 25.2%. It has been tracked across 399 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for SEROQUEL XR 200 MG TABLET?
Since Nov 28, 2013, the NADAC for SEROQUEL XR 200 MG TABLET has ranged from a low of $12.2854 (Dec 18, 2013) to a high of $15.7533 (Dec 12, 2018), with a median of $15.5531 per EA.
Are there cheaper alternatives to SEROQUEL XR 200 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, QUETIAPINE FUMARATE 200 MG TAB, is $0.0857 per EA — about 99% below SEROQUEL XR 200 MG TABLET.
Who manufactures SEROQUEL XR 200 MG TABLET?
SEROQUEL XR 200 MG TABLET (NDC 00310028260) is labeled by AstraZeneca Pharmaceuticals LP, and CMS classifies it as a brand product.